This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Ajovy® Alternatives

Ajovy®

(Fremanezumab)
Ajovy
    Migraine
  • Vyepti®
  • Aimovig®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Ajovy is a prescription medication that can be self-injected once a month or once every three months under the skin to prevent migraine headaches. The most commonly reported side effect is injection site reactions. Ajovy does not seem to cause constipation. Additionally, there are no known drug interactions. Ajovy is FDA approved for the following indications: Migraine prevention.

Emgality®

(Galcanezumab)
Emgality
    Migraine
  • Vyepti®
  • Aimovig®
  • Nurtec ODT®
  • Ubrelvy®
  • Qulipta®
Prescription Only
Emgality is a medication that can be self-administered once a month by injecting it subcutaneously under the skin. It is used for migraine prevention in adults and can also be used to treat cluster headaches during a cluster headache period. The most frequently reported side effect is injection site reactions. Additionally, there are no known drug interactions with Emgality. Emgality is FDA approved for the following indications: Migraine and Cluster Headaches.

Dosage & Administration

Administration
Subcutaneous
Subcutaneous
Dosing
225 mg monthly or 675 mg every 3 months (as three consecutive injections of 225 mg each)
Migraine: 240 mg loading dose (120 mg x 2) followed by 120 mg monthly.
Latin Shorthand
225 mg/mo or 675 mg q3mo
240 mg LD (120 mg x 2) then 120 mg/mo.

Financial Assistance

Copay
$5
$0
Annual Cap
Patient specific maximum benefit.
$4,900
Assistance Expiration
12/31/2023
12 months
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Ajovy® vs. Vyepti®
  • Ajovy® vs. Aimovig®
  • Ajovy® vs. Nurtec odt®
  • Ajovy® vs. Ubrelvy®
  • Ajovy® vs. Qulipta®

Relevant Resources

Emgality
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Ajovy
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.